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Abstract: CD4+ T-lymphocyte destruction, microbial translocation, and systemic immune activation
are the main mechanisms of the pathogenesis of human immunodeficiency virus type 1 (HIV)
infection. To investigate the impact of HIV infection and antiretroviral therapy (ART) on the immune
profile of and microbial translocation in HIV-infected children, 60 HIV vertically infected children
(31 without ART: HIV(+) and 29 with ART: ART(+)) and 20 HIV-uninfected children (HIV(´))
aged 2–12 years were recruited in Vietnam, and their blood samples were immunologically and
bacteriologically analyzed. Among the HIV(+) children, the total CD4+-cell and their subset (type
1 helper T-cell (Th1)/Th2/Th17) counts were inversely correlated with age (all p < 0.05), whereas
regulatory T-cell (Treg) counts and CD4/CD8 ratios had become lower, and the CD38+HLA (human
leukocyte antigen)-DR+CD8+- (activated CD8+) cell percentage and plasma soluble CD14 (sCD14,
a monocyte activation marker) levels had become higher than those of HIV(´) children by the age of
2 years; the CD4/CD8 ratio was inversely correlated with the plasma HIV RNA load and CD8+-cell
activation status. Among the ART(+) children, the total CD4+-cell and Th2/Th17/Treg-subset counts
and the CD4/CD8 ratio gradually increased, with estimated ART periods of normalization being
4.8–8.3 years, whereas Th1 counts and the CD8+-cell activation status normalized within 1 year of ART
initiation. sCD14 levels remained high even after ART initiation. The detection frequency of bacterial
16S/23S ribosomal DNA/RNA in blood did not differ between HIV-infected and -uninfected children.
Thus, in children, HIV infection caused a rapid decrease in Treg counts and the early activation of
CD8+ cells and monocytes, and ART induced rapid Th1 recovery and early CD8+-cell activation
normalization but had little effect on monocyte activation. The CD4/CD8 ratio could therefore be an
additional marker for ART monitoring.
Keywords: HIV-infected children; intestinal microbial translocation; immune activation; 16S/23S
ribosomal DNA
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1. Introduction
Mucosa-associated lymphoid tissues, such as the gut-associated lymphoid tissue (GALT), harbor
approximately 40%–60% of lymphocytes in the human body. GALT is the largest replication site and
reservoir of human immunodeficiency virus type 1 (HIV) among HIV-infected individuals. In the
early stages of HIV infection, the remarkable destruction of CD4+ T (CD4+) cells, particularly the
type 17 helper T-cell (Th17) subset, occurs in GALT [1–3], resulting in the decline in the immune and
mechanical barrier functions of the gut mucosa. Subsequently, the translocation of microbial products,
such as lipopolysaccharides from gram-negative bacteria and bacterial DNA, from the gastrointestinal
tract to systemic circulation occurs, which induces systemic immune activation, disrupts immune
balance, and causes further loss of CD4+ cells [3–6]. CD4+ cells in the peripheral blood recover
1–3 years after antiretroviral therapy (ART) initiation, whereas the recovery of CD4+ cells in GALT is
much slower. The barrier function of the gut mucosa therefore remains impaired, and the immune
activation continues for many years after ART initiation [3,7,8].
Children who have contracted HIV from their mothers (vertical infection) progress to acquired
immunodeficiency syndrome (AIDS) more rapidly than HIV-infected adults, showing a more rapid
decline in CD4+-cell counts and high plasma HIV viral load (VL). Without ART, more than 50% of these
children die by the age of 2 years [9,10]. In children, there is an abundance of lymphoid aggregates in
the gut submucosa and memory CD4+CCR5+ T cells in gut epithelial cells [11]. Because these cells are
highly susceptible to HIV infection even without activation, they are likely to be the prime site of HIV
infection and replication [9,11]. Furthermore, a relatively low HIV-specific Th1 response coinciding
with a low Th1/Th2 ratio and an expanded population of regulatory T cells (Tregs) are observed
among HIV-infected children, particularly among infants [9,12,13]. HIV-infected children also exhibit
a decrease in CD4+-cell counts, CD8+-cell activation, and intestinal microbial translocation [14,15],
and ART effectively restores CD4+-cell populations and suppresses CD8+-cell activation [14,16,17], as
is the case among HIV-infected adults. However, the impact of HIV infection and ART on different
CD4+-cell subsets (Th1, Th2, Th17, and Treg) in children remains poorly understood.
Since 2008, we have followed up with HIV-infected children in Hanoi, Vietnam to find an
efficient and cost-effective method and immunological markers for monitoring ART in resource-limited
settings [18]. Based on the results of that field study, we conducted this cross-sectional study to clarify
the impact of HIV infection and ART on the immune profile and microbial translocation status of
children aged over 2 years who have an immune status considered to be relatively mature and
stable [9,19,20].
2. Results
2.1. Characteristics of the Subjects
This study included 60 HIV vertically infected children (31 without ART (HIV(+)) and 29 with
ART (ART(+)) and 20 HIV-uninfected healthy children (HIV(´)). The characteristics of the study
subjects are shown in Table 1. The ART(+) children had received ART for a median period of 3.5 years,
and 22 (75.9%) had an undetectable plasma VL (< 220 copies/mL). More ART(+) (5/29, 17.2%) than
HIV(+) (1/31, 3.2%) children were at WHO clinical stage 2, although the difference was not statistically
significant (p = 0.098). The HIV(+) and ART(+) children were 2 years older than the HIV(´) children
(HIV(+) vs. HIV(´): median age 6.2 vs. 4.1 years, respectively, p = 0.034; ART(+) vs. HIV(´): median
age 6.1 vs. 4.1 years, respectively, p = 0.009), although height and body weight did not significantly
differ among the three groups (all p > 0.1).
2.2. Immune Status of HIV-Infected Children
The immune statuses of the children in the three groups are shown in Table 1. Compared with
the HIV(´) children, the HIV(+) children had significantly lower total CD4+-cell (p = 0.003) and
Th1/Th2/Th17/Treg-subset counts (p = 0.003/0.016/<0.001/<0.001, respectively), a lower percentage
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of CD4+ cells in lymphocytes (p = 0.001), a higher percentage of CD8+ cells in lymphocytes (p < 0.001),
a lower CD4/CD8 ratio (p < 0.001), and a higher percentage of CD38+HLA (human leukocyte
antigen)-DR+CD8+ cells in CD8+ cells (activated CD8+ cells, p < 0.001), although CD8+-cell counts
and the CD4+-cell activation status (percentage of CD38+HLA-DR+CD4+ cells in CD4+ cells) did not
significantly differ between the two groups (p = 0.239 and 0.969, respectively). The HIV(+) children had
higher plasma soluble CD14 (sCD14; a monocyte activation marker) levels than the HIV(´) children
(p = 0.009).
The ART(+) children had significantly lower total CD4+-cell (p = 0.018) and Th2/Th17/Treg-subset
counts (p = 0.009/<0.001/0.004), a lower CD4/CD8 ratio (p = 0.001), and higher sCD14 levels (p < 0.001)
than the HIV(´) children. However, the CD4+-cell percentage in lymphocytes (p = 0.404), Th1 count
(p = 0.611), and activated CD8+-cell percentage (p = 0.329) did not significantly differ between the
two groups.
TheART(+) children had significantly higher Th1//Th17/Treg-subset counts (p = 0.002/0.016/<0.001),
higher sCD14s levels (p < 0.001), and lower activated CD8+ percentages (p < 0.001) than the HIV(+)
children. However, the total CD4+-cell (p = 0.429) and Th2-subset counts (p = 0.970) and the CD4/CD8
ratio (p = 0.181) did not significantly differ between the two groups.
Table 1. Characteristics and immune status of each group.








Age (years) * 6.2 (2.0–11.0) 4.1 (2.0–8.3) 6.1 (3.6–8.6) 0.034 0.009 0.584
Gender, female (n)/male (n) * 14/17 8/12 12/17 0.718 0.920 0.764
Height (cm) * 109.0 (77.0–129.5) 110.0 (80.0–130.0) 110.0 (90.0–130.0) 0.771 0.418 0.539
Body weight (kg) * 17.5 (10.0–27.0) 16.0 (9.0–35.0) 19.8 (12.0–32.8) 0.395 0.140 0.192
WHO clinical stage:
2 (n)/1 (n) 1/30 5/24 - - 0.098
ART duration (years) * 3.5 (0.8–5.8) - - -
Viral load (log10 copies/mL) * 5.0 (3.2–6.5) ** - - < 0.001
% CD4+ * 22.1 (3.6–44.5) 29.5 (19.6–54.9) 28.8 (12.4–47.1) 0.001 0.404 0.010
CD4+-cell counts (cells/µL) * 698 (97–1784) 1050 (693–2688) 894 (244–1711) 0.003 0.018 0.429
Th1 counts (cells/µL) * 80 (25–227) 136 (74–220) 147 (49–211) 0.003 0.611 0.002
Th2 counts (cells/µL) * 537 (63–1375) 822 (413–2196) 553 (119–1369) 0.016 0.009 0.970
Th17 counts (cells/µL) * 45 (6–116) 109 (51–192) 58 (23–144) <0.001 <0.001 0.016
Treg counts (cells/µL) * 14 (0–133) 48 (16–94) 30 (9–71) <0.001 0.004 <0.001
%CD38+HLA-DR+/CD4 * 5.6 (2.2–17.3) 6.4 (2.7–27.6) 4.3 (2.0–15.6) 0.969 0.036 0.003
% CD8+ * 43.4 (29.5–61.4) 31.4 (23.5–43.3) 44.7 (31.1–61.4) <0.001 <0.001 0.464
CD8+-cell counts (cells/µL) * 1368 (470–3127) 1101 (634–2874) 1212 (769–2064) 0.239 0.290 0.631
%CD38+HLA-DR+/CD8 * 27.5 (12.2–53.3) 12.9 (5.8–38.6) 10.2 (5.0–27.7) <0.001 0.329 <0.001
CD4/CD8 * 0.50 (0.06–1.19) 1.03 (0.45–2.34) 0.66 (0.20–1.42) <0.001 0.001 0.181
sCD14 (ng/mL) * 1637 (1049–3003) 1413 (944–2580) 1964 (1281–3169) 0.009 <0.001 <0.001
HIV(+): Children infected with HIV and without ART; ART(+): Children infected with HIV and on ART; HIV(´):
Children not infected with HIV. P values are from the Man-Whitney U test, except the p values for sex and
WHO clinical stage comparison, which are from the chi square test or Fisher’s exact test. * Median (range);
** 22 ART(+) children with undetectable viral load.
2.3. Impact of HIV Infection on Immune Profile
Among the HIV(+) children, the total CD4+-cell counts (Figure 1A, p = 0.007), Th1/Th2/Th17-subset
counts (Figure 1B–D, p = 0.040/0.012/0.024, respectively), CD4+-cell percentage in lymphocytes
(Figure 1F, p = 0.033), and CD8+-cell counts (Figure 1G, p = 0.060) were inversely correlated with
age (that is, nearly equal to their HIV-infection period). On the other hand, Treg counts (Figure 1E)
and the CD4/CD8 ratio (Figure 1J) were lower and the CD38+HLA-DR+CD8+- (activated CD8+) cell
percentage (Figure 1I) and plasma sCD14 levels (Figure 1K) were higher than those of the HIV(´)
children by the age of 2 years. The CD38+HLA-DR+CD4+- (activated CD4+) cell percentage was not
significantly correlated with age (Figure 1H). The activated CD8+-cell percentage (Figure 1L, p < 0.001)
and sCD14 levels (Figure 1M, p = 0.030) were positively correlated with the plasma VL. The CD4/CD8
ratio was inversely correlated with the plasma VL (Figure 1N, p = 0.045) and CD8 activation status
(Figure 1O, p = 0.003).
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2.4. Impact of ART on the HIV-Induced Immune Profile
Among the ART(+) children, the total CD4+-cell counts (Figure 2A, p = 0.001), Th2/Th17/Treg-subset
counts (Figure 2C–E, p = 0.001/0.001/0.030, respectively), CD4+-cell percentage in lymphocytes
(Figure 2F, p = 0.001), and CD4/CD8 ratio (Figure 2J, p = 0.001) gradually, but significantly, increased
during ART, whereas the Th1 counts had increased to the range of those of the HIV(–) children by
around 1 year of ART initiation (Figure 2B). The CD8+-cell counts were not significantly correlated
with ART duration. None of these markers were significantly correlated with age (data not shown).
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immunological markers to reach the median values of the HIV(´) children. The estimations were as
Int. J. Mol. Sci. 2016, 17, 1245 6 of 13
follows: 4.8 years (95% confidence interval (CI): 2.7–7.0 years) of ART for the total CD4+-cell counts,
3.6 years (95% CI: 1.4–5.7) for the CD4+-cell percentage in lymphocytes, 5.6 years (95% CI: 3.4–7.9) for
the Th2 counts, 8.2 years (95% CI: 6.2–10.2) for the Th17 counts, 8.3 years (95% CI: 3.4–12.2) for the
Treg counts, and 6.6 years (95% CI: 4.5–8.7) for the CD4/CD8 ratio.
During the first year of ART initiation, the percentage of activated CD8+ cells rapidly decreased
to the upper range of that among the HIV(–) children and then continued to slowly, but significantly,
decrease (Figure 2I, p = 0.010). In contrast, the percentage of activated CD4+ cells marginally decreased
with ART duration (Figure 2H, p = 0.053), but the percentage of activated CD4+ cells even among
the HIV(+) children did not significantly differ from that among the HIV(´) children (5.6% vs. 6.4%,
p = 0.969, Table 1). The plasma sCD14 levels showed no significant changes during almost 6 years of
ART (Figure 2K).
The CD4/CD8 ratio was inversely correlatedwith the percentage of activated CD8+ cells (p = 0.003,
Figure 2L).
2.5. Physiological Change in Immunological Markers with Age among the HIV(´) Children
Among the HIV(´) children, only the percentage of activated CD8+ cells significantly decreased
with age (p = 0.023, Figure 3I), and plasma sCD14 levels marginally decreased with time by 4 years of
age and remained stable thereafter (p = 0.066, Figure 3K). The other immunological markers did not
show significant relationships with age (Figure 3A–H,J,L).
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Bacter ides fragilis. p values: Fisher’s exact probability test.
3. Discussion
In the current study, we investigated the impact of HIV infection and ART on the immune profile
of children aged over 2 years. Among the HIV(+) children, the total counts of CD4+ cells and their
subsets (Th1/Th2/Th17) were inversely correlated with age, whereas Treg counts, CD38+HLA (human
leukocyte antigen)-DR+CD8+- (activated CD8+) cell percentage, and plasma sCD14 levels (activated
monocyte level) were not. By the age of 2 years, Treg counts had become lower and the activated CD8+
cell and monocyte levels had become higher than those of the HIV(´) children. In addition, activated
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CD8+ cell and monocyte levels were positively correlated with VL, and the CD8+-cell activation status
was inversely, although marginally, correlated with Treg counts, (p = 0.0575). These findings indicate
that vertical HIV infection induces a rapid decrease in the Treg subset and the early activation of
CD8+ cells and monocytes. These data suggest that the early decline in Tregs contributes to CD8+-cell
activation in the early phase of HIV infection in children, as previously reported in adults [21]. The early
activation of CD8+ cells after HIV infection [15,16] and a correlation between CD8+ cell activation and
VL [22] have been previously reported, whereas a rapid decrease in Treg subset has not been previously
reported in children, although it has been reported in adults with primary HIV infection [23].
Among the ART(+) children, Th2/Th17/Treg-subset counts were positively correlated with ART
duration and were estimated to reach the levels of HIV(´) children after 5.6, 8.2, and 8.3 years of ART
initiation, respectively, compared with an estimate of only 1–2 years for Th1 counts. The activated
CD8+ cell percentage decreased to the level of the HIV(´) children during the first year of ART
initiation, whereas the plasma sCD14 level (activated monocytes level) was maintained at a level
higher than that of the HIV(´) children even after VL was controlled and CD8+-cell activation was
normalized. These findings indicate that in children, ART induced a more rapid Th1 recovery than
the Th2/Th17/Treg subsets and a rapid normalization of CD8+-cell activation but had little effect on
monocyte activation. Although previous studies have reported the early normalization of CD8+-cell
activation after ART initiation [16,24], the recovery profile of CD4+-cell subsets after ART initiation,
particularly the rapid recovery of Th1 and the slower recovery of Th2/Th17/Treg, has not been
reported before in children. Incidentally, the rapid recovery of Th1 may play a role in the control
of HIV infection together with ART. Similar to our findings, a previous study has reported that the
plasma sCD14 level is not normalized even after 2 years of ART initiation in children, although it
is significantly reduced after ART initiation [25]. Because the sCD14 level has been proposed as
an independent predictor of non-AIDS-defining morbidity events even during suppressive ART in
HIV-infected adults [26,27], further longitudinal studies may be needed to elucidate the implication of
the high monocyte activation status in HIV-infected children under ART.
Among the HIV(+) children, the CD4/CD8 ratio was inversely correlated with the plasma VL and
the activated CD8+-cell percentage. Among the ART(+) children, the CD4/CD8 ratio was positively
correlated with ART duration, as were the total CD4+-cell and Th2/Th17/Treg-subset counts, and
inversely correlated with the percentage of activated CD8+ cells. Recent studies have suggested
that the CD4/CD8 ratio is a marker of T-cell activation, senescence, and activation/exhaustion in
treated HIV-infected children and young adults, and that it could be independently associated with the
risk of non-AIDS-related morbidity and mortality [28,29]. Given the cost effectiveness of measuring
CD4+ and CD8+ cell levels in clinical laboratories, the CD4/CD8 ratio could be used as an additional
immunological marker to monitor ART outcomes, particularly in resource-limited settings.
Intestinal microbial translocation plays a role in the pathogenesis of HIV infection [6].
Furthermore, immune activation is driven by intestinal microbial translocation in HIV-infected children
both before and after ART [22,30]. However, in this study, none of the targeted bacterial 16S/23S
rRNA fragments were detected in whole blood samples of the 80 study participants, indicating that
live bacteria (bacteremia) are rarely detected in HIV-infected and -uninfected children. In contrast,
bacterial rDNA was detected in 8 HIV(+) children and 3 HIV(´) children, and the detection frequency
of staphylococcal rDNA was significantly higher among the HIV(+) children than among the ART(+)
children (22.6% vs. 0%, respectively). However, there was no significant association of the copy number
of bacterial 16S/23S rDNA with CD8+-cell or monocyte activation and no significant difference in
the frequency of bacterial rDNA between the HIV(+) and HIV(´) children. These data suggest that
ART decreases the occurrence of intestinal microbial translocation in HIV-infected children, although
the possibility of contamination with Staphylococcus epidermidis cannot be excluded. Thus, further
studies are needed to elucidate the reasons for the discrepancies between our data and previous
findings [22,30] in relation to microbial translocation in HIV-infected children.
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In this study, we recruited children who were over 2 years of age because their immune systems
are considered to be relatively mature and stable [9,19,20]. We showed that all targeted immunological
markers, except CD8+-cell activation, did not significantly change with age among the HIV(–) children
(Figure 3). These data demonstrate that the results presented here on the impact of HIV infection and
ART on the immune profile of children were not influenced by growth-related physiological changes.
There are some limitations to this study. First, this was a cross-sectional study rather than a
longitudinal study; Second, the number of study subjects was relatively small, which limited our
findings in relation tomicrobial translocation; Third, the HIV(+) and ART(+) childrenwere 2 years older
than the HIV(´) children; Finally, only cell-surface markers were used to identify the CD4+-subsets,
particularly Treg. Therefore, these findings should be confirmed by longitudinal studies following
HIV-infected children before and during ART with age-matched controls.
To our knowledge, this is the first study to investigate the impact of HIV infection and ART on
the immune profile of CD4+-cell subsets (Th1/Th2/Th17/Tregs) concurrently with the activation of
T cells and monocytes in children. We found that HIV infection induced a more rapid decline in the
Treg subset than in the Th1/Th2/Th17 subsets and the early activation of CD8+ cells and monocytes.
We also found that ART induced a more rapid recovery of the Th1 subset than the Th2/Th17/Treg
subsets and the early normalization of CD8+-cell activation but that it had little effect on the activation
of monocytes in children. Finally, we have provided evidence that the CD4/CD8 ratio is an additional
marker for ART outcomes.
4. Materials and Methods
4.1. Subjects and Study Design
Sixty Vietnamese children vertically infected with HIV were recruited in May 2012. These children
were assigned to one of two groups: the HIV(+) group and the ART(+) group. The HIV(+) group
comprised 31 children with HIV who did not receive ART; the female/male ratio was 14/17, and
the median age was 6.2 years (2.0–11.0 years). The ART(+) group comprised 29 children with HIV
who had been treated with ART; the female/male ratio was 12/17, and the median age was 6.1 years
(3.6–8.6 years). The study inclusion criteria for these HIV-1-infected groups were as follows: the
children (1) had been followed at the National Hospital of Pediatrics (NHP) in Hanoi, Vietnam; and
(2) were more than 2 years of age because at this point the immune system is relatively mature and
stable [9,19,20]. The exclusion criteria were as follows: children who (1) had progressed to AIDS;
(2) had received any treatment within the prior 8 weeks that might influence the immune system; and
(3) had symptoms of gastrointestinal infections at the time of recruitment. The children in the ART(+)
group resided at an orphanage center near Hanoi; the children in the HIV(+) group were followed at
the outpatient department of NHP. A third control group, the HIV(´) group, was also included and
comprised 20 healthy Vietnamese children without HIV infections. The female/male ratio was 8/12,
and the median age was 4.1 years (2.0–8.3 years). The children in this group resided at an orphanage
center near Hanoi. The characteristics of the study subjects are shown in Table 1.
At recruitment, the median ART duration in the ART(+) group was 3.5 years (0.8–5.8) years. Of the
29 children, 8 received zidovudine (AZT)/lamivudine (3TC)/nevirapine (NVP), 7 received stavudine
(d4T)/3TC/NVP, 6 received AZT/3TC/efavirenz (EFV), 4 received d4T/3TC/EFV, 2 received
AZT/3TC/lopinavir boosted with ritonavir (LPV/r), 1 received abacavir (ABC)/3TC/LPV/r, and
1 received ABC/didanosine/LPV/r.
The protocol of this cross-sectional study was approved by the Ethics Committee of Kanazawa
University in Japan and the Ethics Committee of NHP in Vietnam. All of the HIV-infected children who
met the inclusion criteria and did not correspond to the exclusion criteria, and all of the HIV-uninfected
children who resided in the orphanage and were eligible for the criteria, were invited to join this study.
The family or guardian of each subject was informed, and only those who voluntarily consented to
participate were recruited. Written consent was obtained from all participants.
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4.2. Plasma HIV VL and sCD14 Concentration
Plasma HIV VL was measured using a Cobas Taqman HIV-1 Test Kit version 1.0 (Roche Molecular
Systems, Inc., Branchburg, NJ, USA), following the manufacturer’s instructions (detection limit:
40 copies/mL). Plasma samples were diluted to 1:5.5 for measurements, which resulted in a final
detection limit of 220 copies/mL.
Plasma sCD14 concentration was measured with a Human sCD14 Immunoassay Kit (R&D Systems,
Minneapolis, MN, USA), following the manufacturer’s instructions.
4.3. Immunological Analysis
Immune activation was evaluated based on the percentage of CD4+ and CD8+ lymphocytes
expressing CD38 and major histocompatibility complex class II (HLA-DR) molecules [31]. The different
CD4+-cell subsets were identified using cell-surface markers: CXCR3+CCR6´CD4+ (“Th1”),
CXCR3´CCR6´CD4+ (“Th2”), CXCR3´CCR6+CD4+ (“Th17”) [32], and CD25highCD4+ (“Treg”) [33].
Blood samples were processed for cell staining within 6 h after collection. Whole blood samples
(50 µL) were stained for 15 min at 4 ˝C with a combination of four monoclonal antibodies: anti-CD4
PerCP and CD8 PE (BD Biosciences, San Jose, CA, USA), CD38 FITC (Miltenyi Biotec, Auburn, AL,
USA), andHLA-DR PE-Cy7 (Biolegend, San Diego, CA, USA). Alternatively, samples were stainedwith
a combination of four anti-CD4 monoclonal antibodies: anti-CD4 PerCP and CD25 PE (BD Biosciences),
and CXCR3 FITC and CCR6 PE-Cy7 (Biolegend). After red blood cells were lysed with a lysing buffer
(BD Biosciences), the remaining cells were washed once with 1 mL of phosphate buffered saline (PBS),
kept at 4 ˝C in PBS with 1% paraformaldehyde and 0.5% bovine serum albumin, and analyzed within
48 h after staining at Kanazawa University with a JSAN flow cytometer (Bay Bioscience, Kobe, Japan).
The data were analyzed with Flowjo V.7.5.5 (FLOWJO, OR, USA).
4.4. Detection of Bacterial Ribosomal RNA Genes (rDNA) in Plasma
Isolated plasma (100 µL) was used for DNA extraction with the SMI TEST EX R&D (Medical and
Biological Laboratories Co., Ltd., Aichi, Japan), following the manufacturer’s instructions. qPCR was
then performed with a TaKaRa Taq kit (TaKaRa Bio Inc., Shiga, Japan). The reaction mixture (10 µL)
contained 5 µL of template DNA and 0.2 µM of each specific primer set, except for the primer targeting
g-Bfra-F2/g-Bfra-R (0.4 µM). The primers were designed to target bacterial 16S or 23S rRNA genes
(Table S1). The amplification program comprised one cycle at 94 ˝C for 5 min and 45 cycles at 94 ˝C for
20 s, 55 ˝C or 60 ˝C for 20 s, and 72 ˝C for 50 s. A standard curve was generated with qPCR data and
cycle threshold (Ct) values. The target gene copy number in the plasma samples was determined in
a sample of the extracted DNA (1/20 of the DNA extracted from 100 µL of plasma). This DNA was
subjected to qPCR, and the Ct value was applied to the standard curve to obtain the corresponding
bacterial rDNA copy number/µL of plasma. With this procedure, the lower detection limit for the
targeted gene was 2 copies/µL of plasma.
4.5. Detection of Bacterial rRNA in Blood
Peripheral blood (1 mL) was added to two volumes of the RNA Protect bacterial reagent (QIAGEN
GmbH, Hilden, Germany). After centrifugation of the mixture at 14,000ˆ g for 10 min, the supernatant
was discarded and the pellet was stored at ´80 ˝C until further use. Total RNA extraction was
followed by RT-qPCR as previously described [34]. Each RNA sample was diluted; then, diluted
samples (corresponding to amounts of 1/200 and 1/20 of the extracted RNA from 1 mL of blood)
were subjected to RT-qPCR with specific primer sets that targeted bacterial 16S/23S rRNA [34,35]
to investigate if live bacteria existed in the blood stream of the study subjects (Table S1). With this
procedure, the lower detection limit for the targeted bacteria was 4 cells/mL of blood.
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4.6. Statistical Analysis
Statistical analyses were performed with the SPSS programs (IBMSPSS statistics 19, IBM
Corporation, NY, USA). The Mann–Whitney U test was used to compare the markers among the
three groups (HIV(´), HIV(+),and ART(+)). Fisher’s exact test or the chi square test was used to
compare the detection frequency of bacterial rDNA in plasma, sex distribution, and the WHO clinical
stage across the groups. Spearman’s rank correlation was used to analyze the correlation among the
biological markers in each group. p-values < 0.05 were considered statistically significant.
5. Conclusions
In children, HIV infection caused a rapid decrease in Treg counts and the early activation of
CD8+ cells and monocytes, and ART induced rapid Th1 recovery and early CD8+-cell activation
normalization but had little effect on monocyte activation. The CD4/CD8 ratio could be an additional
marker for ART monitoring.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/17/8/
1245/s1.
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